Objectives: To evaluate the proficiency of Spanish laboratories regarding accurate susceptibility testing, detection and interpretation of Pseudomonas aeruginosa b-lactam resistance phenotypes.
Introduction
Pseudomonas aeruginosa is one of the most relevant human opportunistic pathogens and one of the top aetiological agents causing severe acute nosocomial infections, particularly burn wound infections and ventilator-associated pneumonia in intensive care unit patients, as well as chronic lung infections in patients with chronic respiratory diseases such as cystic fibrosis. 1, 2 One of the most striking features of this species is its remarkable capacity for antibiotic resistance development. 3 -5 The prevalence of infections caused by multidrug-resistant, extensively drug-resistant and even pan-drug-resistant P. aeruginosa strains is increasing globally, often making antibiotic treatments useless and causing a significant rise in the morbidity and mortality of the affected patients. Such strains, often belonging to so-called high-risk clones, are eventually the cause of large outbreaks and/or endemic situations in multiple hospitals/ regions worldwide. 5 -7 The outstanding antimicrobial resistance (potentially affecting all families of antibiotics) that this microorganism may achieve is based on the conjunction of its high intrinsic resistance, its extraordinary capacity for additional development through the selection of chromosomal mutations and the acquisition of transferable determinants on mobile elements such as integrons, transposons and/or plasmids. 3 The mutation-driven mechanisms include the loss of OprD porin, conferring resistance to imipenem, hyperproduction of the chromosomal cephalosporinase AmpC, causing resistance to all penicillins and cephalosporins, and the overexpression of one or more of several efflux pumps (such as MexAB-OprM, MexCD-OprJ, MexEF-OprN and/or MexXY-OprM) encoded in the P. aeruginosa genome, which can lead to resistance or decreased susceptibility to b-lactams, fluoroquinolones and aminoglycosides. 4, 5, 8 Among the horizontally acquired resistance determinants, the carbapenemases are probably those most concerning, because of their fast worldwide spread and their wide spectrum of hydrolysis, affecting virtually all b-lactams. 4, 5 Class B carbapenemases [also called metallo-b-lactamases (MBLs)] hydrolyse all b-lactams with the only exception of monobactams, and are those most frequently detected in clinical isolates of P. aeruginosa, mainly the variants belonging to the IMP or VIM groups. 9, 10 Nevertheless, other lessfrequent MBL groups have also been reported in this species, including SPM, GIM, AIM and NDM enzymes. 11 -14 Carbapenemases of classes A (GES-2, GES-5, KPC-2 and KPC-5) and D (OXA-40 and OXA-198) have also been detected in P. aeruginosa. 15 -20 Finally, extended-spectrum b-lactamases (ESBLs) are also globally increasing in P. aeruginosa clinical strains, implying an obvious epidemiological threat, and are mainly represented by different variants of the groups PER, GES, VEB (class A) and OXA (class D). 9 With the exception of a few national-scale surveys, 21 knowledge of the global epidemiology of all these acquired b-lactamases is still very limited, due to the absence of fully reliable detection protocols in P. aeruginosa and limited active surveillance.
In this scenario, the prevention of resistance development by implementing appropriate treatments and antibiotic use policies, and the control of epidemiologically dangerous strains, seem key factors in improving the management of P. aeruginosa infections. 22 The ability of the clinical microbiologist to perform proper antimicrobial susceptibility testing and interpretation and to carry out proficient complementary phenotypic/genotypic tests to detect the resistance mechanisms constitutes an essential initial step in optimizing these measures. 23, 24 In this regard, the high level of P. aeruginosa intrinsic resistance and the frequent mutation-driven mechanisms significantly increase the difficulty of detecting horizontally acquired determinants, which may often be missed. 25 These circumstances provide a worrying consequence, which is the underestimation of the prevalence of acquired and/or mutational resistance mechanisms, which often leads to the application of erroneous antibiotic treatments and subsequent clinical failure. 26 There is, however, very limited information on the proficiency of clinical microbiology laboratories in overcoming this challenge. One of the few examples is a previous multicentre study carried out in Spain in 2001, in which the ability of 52 clinical microbiology laboratories to correctly evaluate the resistance to b-lactams of several wellcharacterized strains of Enterobacteriaceae and P. aeruginosa was analysed. 27 However, the evaluated P. aeruginosa strains only included representatives showing simple mutation-driven resistance mechanisms and none carried the most concerning transferable resistance mechanisms. Hence, the objective of this work was to assess the ability of the Spanish clinical microbiology laboratories to properly carry out susceptibility testing and inference of resistance mechanisms in a collection of well characterized P. aeruginosa strains showing complex combinations of mutational and transferable b-lactam resistance mechanisms, which represent the current diagnostic challenge. Additional objectives were to analyse the diversity and impact of the methods and breakpoints used for antimicrobial susceptibility testing, the complementary phenotypic/genotypic tests used for the detection of the resistance mechanisms and the implemented infection control measures.
Materials and methods
Bacterial strains, characterization of resistance mechanisms and susceptibility testing Thirteen P. aeruginosa strains, coded CC-01 to CC-13, were selected for this study (Table 1 ). This panel included 11 clinical isolates or laboratory 
Study design
The work was designed as a nationwide proficiency study, involving clinical microbiology laboratories in different Spanish regions. In February 2011, the 13 selected strains (Table 1) were sent to the 54 participating laboratories together with detailed instructions. The participating centres were requested to implement their routine methods for the study of antimicrobial susceptibility, considering the 13 strains as isolated from blood cultures. The participants were requested to fill in an electronic form for each strain, including: (i) the results of the antibiogram [quantitatively, in terms of inhibition zone diameters or MIC values, and qualitatively, in terms of the derived 'raw' clinical categories (RCCs): susceptible (S), intermediate (I) and resistant (R)]; (ii) the breakpoints used (CLSI or EUCAST); (iii) the laboratory methods used (i.e. the type of automatic or manual instrumentation); (iv) the interpreted clinical categories (CCs) (interpretations towards a higher resistance CC; ICCs), when it was considered necessary; (v) the inferred potential mechanism(s) responsible for the b-lactam resistance phenotype; and (vi) the definitive information that they would provide to clinicians, including additional notes about potential production of ESBLs and/or carbapenemases and comments with regard to implementation of infection control measures.
Data analysis
The analysis of results was focused on three aspects: (i) descriptive analysis of the susceptibility testing methods, breakpoints applied, CCs assigned and discrepancies between centres derived from them; (ii) analysis of the errors in susceptibility testing results [minor, major and very major errors (mEs, MEs and VMEs, respectively) defined following standard criteria] compared with reference values; 37 and (iii) analysis of the capacity of the participating laboratories to perform proper complementary tests for the detection of acquired b-lactamases, to infer the underlying resistance mechanisms accurately and to recommend isolation measures for epidemiologically concerning strains.
Results
Descriptive analysis of the susceptibility testing methods, breakpoints applied, CCs assigned and derived discrepancies Ninety-four percent of participating laboratories used automated devices for routine susceptibility testing, including the MicroScan WalkAway (Dade MicroScan Inc., West Sacramento, CA, USA; n¼ 16), Vitek2 (bioMérieux; n¼ 16), Wider (Francisco Soria Melguizo, Madrid, Spain; n¼ 15), Phoenix (BD Biosciences, Sparks, MD, USA; n¼ 2) and Sensititre (Trek Diagnostic systems, Westlake, OH, USA; n¼2). The remaining 6% used manual methods. Nevertheless, several users of automatic devices punctually performed additional manual tests to detect acquired b-lactamases or to check certain borderline susceptibility values. For example, for some antimicrobial/strain combinations, mainly involving the carbapenems, 15% of the specific susceptibility testing determinations were done by Etest, whereas only 2.7% of the overall data were obtained by this manual technique.
CLSI breakpoints were used in 86.1% of the determinations, whereas those of EUCAST were applied in the remaining 13.9%. The overall (all antibiotic/strain combinations) rate of discrepancies exclusively due to the differential use of breakpoints was 1.7%. Aztreonam was often involved in this kind of discrepancy, with particularly high percentages (11%-16.7%) in eight of the strains; the aztreonam/CC-02 (AmpC-hyperproducing strain) combination showed the highest percentage of discrepancies (16.7%). Breakpoint-related discrepancies were also high for piperacillin/ tazobactam in the strains overexpressing AmpC (CC-02 and CC-04) or producing the ESBL PER-1 or the MBL VIM-2 (5.7%-8%) and for meropenem in the OprD deficient/AmpC-hyperproducing strain CC-04 (9.4%). On the other hand, ceftazidime and imipenem did not show breakpoint-related discrepancies.
Although the general trend was that a given hospital used only one categorization (CLSI or EUCAST), the utilization of a breakpoint differing from those usually followed by the specific laboratory was not infrequent for some antibiotic/strain combinations. Thus, the use of CLSI breakpoints ranged from 81.1% to 90.4%, whereas the use of EUCAST breakpoints ranged from 9.6% to 18.9%. The highest percentage of EUCAST breakpoint application correlated with Vitek2 users (with this device these breakpoints are implemented by default). However, not all users of Vitek2 followed EUCAST; in fact, 80% of them changed to CLSI. Not all users of the other automatic devices applied the default CLSI breakpoints.
The ICCs provided by the participants and the discrepancies among them are shown in Figure 1 . A high degree of consensus among centres was observed regarding the wild-type strains and those with high-level resistance patterns, such as CC-06 and CC-09 strains (harbouring PER-1 ESBL and GES-5 carbapenemase, respectively). On the other hand, some antimicrobial/ strain combinations displayed a lower degree of consensus, such as aztreonam and CC-02 (AmpC hyperproducer), imipenem and CC-03 (OprD deficient) and cefepime and CC-12 (moderate AmpC-hyperproducing and MexAB-OprM-hyperexpressing strain). Piperacillin/tazobactam also showed a high level of discrepancies, the situation being worsened by the absence of an intermediate category, mainly in CC-02, CC-04 and CC-08 strains (AmpC hyperproducer, AmpC hyperproducer plus OprD deficiency and VIM-2 producer, respectively).
Only 4.5% of all susceptibility determinations implied a change in the ICC to a higher category. Nevertheless, while the interpretations were rarely observed in wild-type strains, they reached high percentages (close to 25%) for some antibiotic/ strain combinations. Among them were meropenem in CAZ  IPM  MEM  TZP  ATM  FEP  CAZ  IPM  MEM  TZP  ATM  FEP  CAZ  IPM  MEM  TZP  ATM  FEP  CAZ  IPM  MEM  TZP  ATM  FEP  CAZ  IPM  MEM  TZP  ATM  FEP  CAZ  IPM  MEM  TZP  ATM  FEP  CAZ  IPM  MEM  TZP  ATM  FEP  CAZ  IPM  MEM  TZP  ATM  FEP  CAZ  IPM  MEM  TZP  ATM  FEP  CAZ  IPM  MEM  TZP  ATM  FEP  CAZ  IPM  MEM  TZP  ATM  FEP  CAZ  IPM  MEM  TZP  ATM  FEP  CAZ  IPM  MEM CC-04, CC-07 or CC-11) and piperacillin/tazobactam in the strain producing the MBL VIM-2. The analysis was also performed considering the results of the three most frequently used devices (Vitek2, Microscan WalkAway and Wider) separately, and comparing the ICCs obtained with those corresponding to the overall determinations. A trend to underestimate the level of resistance in certain strains when analysing the data on piperacillin/tazobactam was observed, mainly in users of the MicroScan WalkAway and Wider. Hence, there was a consequent discrepancy in the results of Vitek2 users (higher CCs in these users) with regard to the overall data. Overestimation of resistance with a particular device was very unusual and almost exclusively linked to EUCAST breakpoint users.
Analysis of errors (mEs, MEs and VMEs) in susceptibility testing results
The b-lactam MICs, the RCCs obtained after applying CLSI and EUCAST criteria and the consensus ICCs obtained by the two reference centres are shown in Table 2 . The distribution of discrepancies and categorical error rates by antibiotics and strains are shown in Tables 3 and 4 , respectively. The percentages of VMEs (false susceptibility) for all b-lactams were low (well below 5%) except for piperacillin/tazobactam (raw and interpreted VMEs 33.3% and 22.6%, respectively). These errors were particularly associated with strain CC-09 (class A GES-5 carbapenemase producer) and almost exclusively observed in users of the automated systems MicroScan WalkAway (50% of the total of the raw VMEs with respect to this antimicrobial and 51% of the interpreted VMEs) and Wider (45% of the total of the raw and 43% of the interpreted VMEs). For MEs (false resistance), percentages were always ,5%, except in the case of cefepime raw MEs (9.4%) and aztreonam interpreted MEs (9.3%). Eighty-five percent of the raw MEs for cefepime occurred in the AmpC-hyperproducing strains CC-02 and CC-04. The high percentage of mEs observed was not surprising, given the MIC values displayed by several of the strains of this collection, which in many cases were on the borderline between two CCs. The analysis of categorical errors by strains (Table 4 ) revealed that those with higher percentages of raw/interpreted VMEs were CC-04 (AmpC hyperproducer and OprD deficient) (5.7/5.7%) and CC-09 (GES-5 producer) (5.6/3.7%). The VMEs in the CC-04 strain were mainly linked to ceftazidime and those in CC-09 to piperacillin/tazobactam. The CC-04 strain was also the one for which the highest percentages of raw MEs (14.8%) were observed, linked to cefepime (83% of them) and meropenem (16% of them), followed by strains CC-02 (AmpC hyperproducer) (7%), linked to cefepime, and CC-11 (a strain overexpressing MexAB-OprM and deficient in OprD) (6.7%), linked to cefepime (57% of them) and ceftazidime (43% of them). This last strain was the one for which the highest percentages of interpreted MEs were detected (11.5%), associated with cefepime (53% of them) and ceftazidime (47%), followed by the CC-07 strain (OXA-161 ESBL producer) with 8.3% of MEs (83% of them for imipenem and 17% of them for meropenem).The Vitek2 was the device showing the lowest percentage of VMEs, followed by the Wider and MicroScan WalkAway. Among all the determinations performed by using Vitek2, only one VME was detected. Regarding the Wider device, eight raw VMEs and five interpreted VMEs were found (affecting piperacillin/tazobactam in the CC-09 strain) and one raw VME/one interpreted VME was found for each of the following combinations: imipenem and the CC-08 strain and ceftazidime and the CC-04 strain. The MicroScan WalkAway was the system showing the highest percentage of VMEs, i.e. piperacillin/tazobactam in strain CC-09 (nine raw VMEs/six interpreted), ceftazidime in strains CC-02, CC-04 (one raw VMEs/one interpreted VME in each strain) and CC-12 (two raw VMEs/two interpreted), imipenem in CC-08 (one raw VME) and aztreonam in CC-12 (one raw VME/one interpreted). Regarding raw MEs, the lowest overall percentage corresponded to the MicroScan WalkAway, followed by the
Capacity of the centres for the detection of acquired b-lactamases, inference of resistance mechanisms and implementation of infection control measures Table 5 shows the results concerning the inference of resistance mechanisms, performance of complementary tests to detect acquired b-lactamases and the recommendation of isolation measures. A large number of centres declined to infer the potential resistance mechanisms in some of the strains, which is logical when affecting the wild-type ones, in which the lack of inference can be interpreted as lack of resistance mechanisms, and then, as wild-type. A very low percentage of inference was also observed in the CC-10 strain (MexCD-OprJ-overexpressing mutant), which was not surprising given that its phenotype was probably the least apparent: hypersusceptibility to almost all b-lactams and aminoglycosides, but enhanced efflux of cefepime and ciprofloxacin, only slightly affecting the derived RCCs. In contrast, strain CC-08 (VIM-2 producer) was the one that provided the largest percentage of inferences (88.5%), and they were successful in up to 82.7% of cases. It was therefore the strain with highest level of success in the inference of the resistance mechanism, probably due to the existence of complementary phenotypic tests widely used in clinical microbiology laboratories, such as the disc diffusion or Etest methods, to detect inhibition of carbapenem resistance by EDTA (Table 5) . By contrast, the percentage of correct inferences was markedly lower for the strains producing the remaining acquired b-lactamases (18% -40%), including the class A carbapenemase (GES-5, CC-09) and ESBLs [PER-1 (CC-06) and OXA-161 (CC-07)], for which the use of specific complementary tests was much more limited (Table 5 ). With the exception of the VIM-2 MBL producer, inference was higher for strains with only mutational mechanisms (CC-02, CC-03, CC-04, CC-05, CC-11 and CC-12) than for those with acquired b-lactamases. The proportion of correct inferences (including partial successes in strains with more than one mechanism) in the cited strains was always at least 40%. The analysis in depth of errors in inferences is shown in Table 6 d NI, not interpreted; antibiotic/strain combinations with S-R discordance between the reference centres were considered as not interpretable and therefore no errors were assigned. In the particular case of piperacillin/tazobactam, given the absence of an I category, the MIC values 32 and 64 mg/L are fully discrepant (S or R) when applying CLSI of EUCAST breakpoints. Thus, any result should be considered as correct and hence there were no possible errors. Furthermore, for some antibiotic/strain combinations (e.g. in strain CC-07) reference ICCs were not defined by the reference laboratories due to the absence of consensus interpretive criteria and therefore no errors could be assigned. e Duplicate determination by the two reference centres using Etest.
aspects was the lack of detection of acquired b-lactamases in certain strains. In these cases, the laboratories exclusively attributed the resistance to mutational mechanisms, mainly in strains CC-06, CC-07 and CC-09, with percentages .25%. The lack of appropriate performance of ESBL/carbapenemase complementary tests, as well as the false negative results in certain cases, played a central role in these misinterpretations of the underlying mechanisms (Table 5 ). In contrast, the mistake of linking the b-lactam resistance with a non-existent horizontally acquired mechanism was most frequently observed in strain CC-04 (22.4%), probably due to false positive results obtained in additional tests or the misinterpretation of the resistance profile ( Table 5 ).
The percentage of recommendation of infection control measures (Table 5 ) was higher for the carbapenemase-producing strains CC-08 and CC-09 ( 40% -45% of centres recommended isolation). However, the percentages of recommendation of isolation for the strains with acquired ESBLs (CC-06 and CC-07) were ,25%. The strains with mutation-driven mechanisms often showed percentages of isolation recommendations much lower than 15%.
Discussion
In the current scenario of growing prevalence and complexity of antimicrobial resistance mechanisms in P. aeruginosa, 38 -40 severely compromising our therapeutic arsenal, the ability of the clinical microbiology laboratory to perform proper and standardized antimicrobial susceptibility testing and interpretation and to perform proficient complementary phenotypic/genotypic tests to detect specific resistance mechanisms is of particular relevance for guiding therapy and infection control strategies. 41 This clinical challenge motivated this large multicentre study, in which we evaluated the proficiency of 54 Spanish laboratories in accurate susceptibility testing and the detection and interpretation of b-lactam resistance phenotypes in a collection of well-characterized P. aeruginosa strains showing complex combinations of mutational and transferable b-lactam resistance mechanisms.
Among the several aspects having a significant impact in the discrepant susceptibility testing results provided by the participating centres, it is worth noting the differential application of nonharmonized CLSI or EUCAST breakpoints. Although EUCAST breakpoints were used in only 14% of the determinations, a significant increase was noted compared with a Spanish multicentre study performed in 2001, in which all centres applied CLSI breakpoints. 27 Moreover, this value is expected to increase significantly in the near future after the current institutional recommendations in Europe are followed. In particular, the application of European breakpoints is expected to increase significantly in Spain soon, due to the constitution in 2012 of the Spanish Antibiogram Committee (Coesant), whose main commitment is the endorsement of EUCAST breakpoints.
Regarding the breakpoint-derived discrepancies, aztreonam was the antibiotic most prone to be affected by such discrepancies. Indeed, wild-type reference strains and those without acquired aztreonam resistance mechanisms are reported as susceptible according to CLSI breakpoints and intermediate according to EUCAST (Table 2 ). This discrepancy might be particularly RCC and ICC results from participating laboratories were compared with the reference centres' values and discrepancies were classified as mE, ME and VME, following standard criteria.
c
For antibiotic/strain combinations with disagreement in only one CC step between the two centres of reference, the most favourable CC for the evaluated centre was chosen. The same approach was followed when an MIC value (obtained by the reference centres) gave rise to two different CCs according to EUCAST/CLSI breakpoints. In this case, the chosen breakpoints were those nearer to concordance with the CC issued by the evaluated centre.
d
The denominator is the number of susceptibility testing determinations per antibiotic.
e
The denominator is the number of susceptible strains per antibiotic.
f
The denominator is the number of resistant strains per antibiotic.
g
The denominator is the total number of susceptibility determinations.
Assessment of P. aeruginosa b-lactam resistance phenotypes relevant for MBL-producing strains (such as CC-08), for which aztreonam might be one of the few available therapeutic options, arguing for the need for harmonized breakpoints. Perhaps more relevant are the discrepancies derived from the different piperacillin/tazobactam breakpoints, because several of the strains showing mutational resistance mechanisms (particularly AmpC overexpression) or relevant acquired b-lactamases such as MBLs are reported as susceptible according to CLSI breakpoints and resistant according EUCAST breakpoints. Fortunately, CLSI piperacillin/tazobactam breakpoints have been modified in 2012 and now the susceptibility breakpoint is the same as that of EUCAST (S ≤16 mg/L). 42 Indeed, this is certainly good news that should be further extended to all other antibiotics through the harmonization of American and European breakpoints.
Another source of discrepant results between centres was the method used for susceptibility testing. Most of the centres (94%) used automatic devices, mainly the MicroScan WalkAway, Vitek2 or Wider systems. Vitek2 was the device showing the lowest percentage of VMEs, followed by the Wider and the MicroScan WalkAway. Regarding raw MEs, the lowest overall percentage corresponded to the MicroScan WalkAway, followed by the Vitek2 and Wider, and after interpretation the highest percentage of MEs was also linked to the MicroScan WalkAway system. Among the tested antibiotics, piperacillin/tazobactam had the highest documented rate of VMEs. Our results were thus consistent with previous studies in which piperacillin/tazobactam was associated with higher rates of VMEs. 43, 44 However, in contrast to these studies, in our multicentre evaluation piperacillin/tazobactam VMEs were exclusively linked to MicroScan WalkAway and Wider users but not to Vitek2 users, perhaps partially due to the more frequent application of the lower EUCAST breakpoints by the users of this system. Also in agreement with these previous studies, 43, 44 cefepime was the antibiotic for which resistance was most frequently overestimated (highest rate of MEs) according to the RCCs. Among the studied strains, CC-04 (AmpC hyperproduction plus OprD deficiency) and CC-09 (GES-5 producer) were those associated with an overall higher rate of VMEs. In agreement with our results, the highest rate of VMEs was also documented for a strain showing AmpC hyperproduction plus OprD deficiency in a multicentre study performed in Spain more than a decade ago, 27 although the panel tested did not include strains producing acquired b-lactamases.
One further source of discrepant results concerns the interpretive reading of susceptibility testing data, and thus the reporting of ICCs. Approximately 4.5% of all susceptibility determinations implied a change in the final CC, reaching percentages close to 25% for some combinations of antibiotic and strain. Indeed, the interpretation of the antibiogram has been recognized as a very relevant tool for providing accurate susceptibility testing results in the clinical microbiology laboratory for more than two decades. 45, 46 There are, nevertheless, several factors well known to limit the efficiency of interpretive reading, such as lack of knowledge about the basis for resistance in a significant proportion of medical microbiologists, unknown factors affecting resistance in clinical strains, low-level resistance mechanisms and camouflage of certain mechanisms because of the complex interplay of intrinsic and acquired resistance mechanisms of P. aeruginosa. 47, 48 The implementation mE ME VME mE ME VME mE ME VME mE ME VME For antibiotic/strain combinations with disagreement in only one CC step between the two centres of reference, the more favourable CC for the evaluated centre was chosen. The same approach was followed when an MIC value (obtained by the reference centres) gave rise to two different CCs according to EUCAST/CLSI breakpoints. In this case, the chosen breakpoints were those nearer to concordance with the CC issued by the evaluated centre. c The denominator is the number of determinations for each strain.
CC
Juan et al. a To consider a mechanism inference as correct, relatively lax criteria were followed. Hence, complete specification of the mutation-driven mechanisms was not required (e.g. the specific name of the hyperexpressed efflux pump). Regarding the acquired b-lactamases, the Ambler's class specification was not required for ESBLs or carbapenemases, with the exception of MBLs (class B). b For strains with more than one mechanism, partially right inferences were considered for those hospitals that only ascertained one of the mechanisms, even if they gave an additional wrong one, provided there were none of the following errors: ignoring the presence of an acquired b-lactamase; attributing resistance to an acquired b-lactamase when the strain only produced mutational mechanisms (or vice versa); giving false positive or negative results for MBLs or ESBLs; and categorizing a strain as wild-type when it was not.
of expert systems in most automatic/semiautomatic devices may help in this task, but although they are generally quite advanced for the interpretation of susceptibility testing in Enterobacteriaceae, their current performance in unravelling the complex repertoire of P. aeruginosa resistance mechanisms is very limited. 49 Expert rules issued by official agencies also refrain from attempting to provide specific recommendations for the interpretation of P. aeruginosa b-lactam susceptibility testing data, likely because these agencies are conscious of the underlying complexity. 50 One of the most relevant historic interpretive reading/resistance mechanism inference rules is the interpretation of extended-spectrum cephalosporin susceptibility data in ESBLproducing Enterobacteriaceae. Rules to interpret carbapenem susceptibility data in carbapenemase-producing Enterobacteriaceae were also implemented later by official agencies. Although neither CLSI nor EUCAST recommends any more specific testing for detection or interpretation of susceptibility data for these acquired enzymes, Enterobacteriaceae breakpoints have been dramatically lowered to minimize the possibility of reporting strains producing relevant ESBLs or carbapenemases as susceptible to extended-spectrum cephalosporins or carbapenems, respectively. While this approach may work for Enterobacteriaceae, it dramatically accentuates the unmet needs for P. aeruginosa. Indeed, recommendations for interpretive reading, resistance mechanism inference or detection have never been issued by CLSI or EUCAST despite the fact that the breakpoints are certainly not adapted to overcome the most frequent resistance mechanisms. As observed in our study, the most relevant mechanisms of mutational resistance to carbapenems (OprD inactivation) and to penicillins and cephalosporins (AmpC hyperproduction and also MeXY-OprM overexpression in the case of cefepime) frequently yield borderline MICs. Therefore, this is a major source of discrepant results if antibiogram interpretive reading is not performed. 51, 52 Borderline b-lactam MICs are also frequently observed for several relevant acquired b-lactamases. Such is the case for piperacillin/tazobactam, particularly when using the 2011 CLSI breakpoints, in MBL-producing strains. 51 Finally, another relevant aspect of this study to be considered is the evaluation of the application of complementary tests for the detection of acquired b-lactamases. Up to 69% of the centres performed specific tests for MBL carbapenemase detection in the VIM-2-producing strain (CC-08), yielding positive results in all cases. Nevertheless, a number of false positive MBL tests were reported for the strain producing the class A carbapenemase GES-5 (CC-09) and some other strains showing complex combinations of mutational and/or transferable resistance mechanisms (Table 5 ). In contrast to MBLs, the application of tests for the detection of ESBLs was far more restricted, since only 22% -24% of the centres applied specific tests in the two ESBL-producing strains included in the study. Moreover, while the applied tests always yielded positive results for the PER-1-producing strain, they yielded negative results for the OXA-161 ESBL in an important proportion of the centres. Indeed, the absence of a reliable test recommended by official agencies for the detection of ESBLs in P. aeruginosa is a further major aspect limiting appropriate susceptibility testing and reporting. Lack of detection of these relevant enzymes may also have important consequences for infection control, since very few centres recommended the application of isolation measures for the ESBL-producing strains, in contrast to what was documented for the MBL-producing strain (Table 5) .
Taken together, the data obtained in this work clearly suggest that the use of different breakpoints and devices, the complexity of the mutation-driven resistance mechanisms and the lack of standard tests to unequivocally detect ESBLs and carbapenemases in P. aeruginosa lead to an extraordinary variability and lack of accuracy in susceptibility testing reports, which may have important consequences in the treatment and control of infections caused by this microorganism. The unification of criteria for susceptibility testing and patient isolation protocols, enhancing clinicians' knowledge about the basis of resistance and accurate determination of the underlying resistance mechanisms are envisaged as pivotal tools in the fight against the growing P. aeruginosa antibiotic resistance pandemics, through the use of individualized treatments adapted to each strain resistance profile and optimized antibiotic use policies and infection control measures.
